Corcept Therapeutics (CORT) Cash & Current Investments (2010 - 2026)

Corcept Therapeutics has reported Cash & Current Investments for 17 years, with the latest figure at $308.2 million in Q2 2026.

• Quarterly Cash & Current Investments fell 9.94% year-over-year to $308.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $308.2 million (down 9.94% YoY) and the FY2025 annual result came in at $372.2 million, down 2.92% from the prior year.
• Cash & Current Investments retreated to $308.2 million in Q2 2026 per CORT's latest filing, from $338.2 million in the prior quarter.
• Over five years, Cash & Current Investments peaked at $473.2 million in Q2 2024 and troughed at $308.2 million in Q2 2026.
• A 5-year average of $380.5 million and a median of $371.1 million in 2022 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments jumped 93.11% in 2022, then declined 27.67% in 2025.
• Over 5 years, Cash & Current Investments stood at $431.7 million in 2022, then retreated by 14.7% to $368.2 million in 2023, then grew by 4.1% to $383.3 million in 2024, then decreased by 2.92% to $372.2 million in 2025, then decreased by 17.19% to $308.2 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $308.2 million, $338.2 million, and $372.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.